Anti-c-Myc Antibody

The c-Myc proto-oncogene encodes a basic helix-loop-helix-leucine zipper transcription factor that drives cell cycle entry, ribosomal biogenesis, glycolytic flux, and mitochondrial programing, and its dysregulation underlies a substantial fraction of Burkitt lymphoma, colorectal carcinoma, and triple-negative breast cancer cases. This unconjugated rabbit polyclonal reagent from Antibodies.com is supplied as 100 µl of liquid antiserum in a single-use vial, validated for western blot, immunohistochemistry, immunofluorescence, and ELISA workflows against human, mouse, and rat samples. Researchers commonly deploy it to characterize MYC overexpression in tumor biopsies, verify CRISPR-edited or tetracycline-inducible constructs carrying a c-Myc epitope tag, and compare proliferating versus quiescent lysate loading controls in HEK293, HeLa, and primary fibroblast cultures. The polyclonal response increases the chance of recognizing multiple epitopes across the N-terminal transactivation domain, an advantage when probing truncated mutants or partial proteolysis products that mask a single linear motif. Store at -20 °C in working aliquots to preserve activity across repeated freeze-thaw cycles; dilute immediately before incubation to limit background from concentrated antisera on fixed tissue sections.